CIK 0001841387
- Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 522214851
- Phone
- +1 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- 4 Open-market sale Chief Technology Officer sold 13,330 shares at $5.97 ($79,625)
- 4 Open-market sale Chief Executive Officer sold 20,293 shares at $5.97 ($121,218)
- 4 Open-market sale See Remarks sold 8,897 shares at $5.97 ($53,145)
- 4 Open-market sale Chief Medical Officer sold 9,769 shares at $5.97 ($58,354)
- 4 Open-market sale Chief Scientific Officer sold 12,645 shares at $5.97 ($75,534)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Shares withheld for taxes Chief Technology Officer gave up 17,328 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Executive Officer gave up 43,443 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Medical Officer gave up 12,175 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 19,748 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 20,153 shares (to pay taxes)
- 4 Grant or award Chief Executive Officer acquired 180,108 shares (grant or award)
Page 6 of 11 · 202 filings